Lupin appoints Abdelaziz Toumi as CEO of manufacturing subsidiary

Lupin has appointed Abdelaziz Toumi as the Chief Executive Officer of its newly formed subsidiary Lupin Manufacturing Solutions (LMS)

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Lupin plans to ramp up its contract manufacturing business for international client and has appointed a seasoned leader as the new CEO.

Abdelaziz Toumi will be the Chief Executive Officer of Lupin's subsidiary Lupin Manufacturing Solutions (LMS), a unit that is starting to build its Contract Development and Manufacturing Operations (CDMO) business for global clients, the pharma major said in a statement on June 17.

Abdelaziz Toumi is regarded as a highly experienced leader in the industry, with over 20 years in the biotech, pharma, and CDMO sectors across Europe, North America, and Asia. Toumi has held leadership roles at Bayer, Merck, Catalent, Lonza, and KBI Biopharma in the past and at Lupin, he will be based in Switzerland, dedicating substantial time to operations in India.

Lupin’s Managing Director, Nilesh Gupta said Abdel "brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global

customers."

Lupin is the third-largest pharmaceutical company in the US on the basis on prescriptions, and runs 15 manufacturing sites and 7 research centers globally. In September 2023, Lupin has carved out a business transfer agreement with LMS to transfer two API manufacturing sites and select R&D operations to the company.